Futibatinib (Lytgobi, Taiho) is indicated for 'the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy'.
The dosage schedule is available in the summary of product characteristics for futibatinib (PDF only).
The list price of futibatinib is £2,386.33 per pack containing 35, 28 or 21 4‑mg tablets (excluding VAT, company submission).
The company has a commercial arrangement. This makes futibatinib available to the NHS with a discount. The size of the discount is commercial in confidence.